Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

26 Jun 2020

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with immunochemotherapy containing rituximab (rituximab, cyclophosphamide, hydroxydaunorubicin-vincristine (Oncovin), and prednisone [R-CHOP]); however, prognosis is extremely poor if R-CHOP fails. To identify genetic mechanisms contributing to primary or acquired R-CHOP resistance, we performed target-panel sequencing of 135 relapsed/refractory...

Source

Identifiers

PMID: 32589730
DOI: 10.1182/bloodadvances.2020001696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphomaPMID 32589730Read ↗

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell Lymphoma by Targeted Gene Sequencing.Semantic proximity Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.Semantic proximity Read ↗

Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapySemantic proximity Read ↗

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrumSemantic proximity Read ↗

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs.Semantic proximity Read ↗

Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.Semantic proximity Read ↗

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.Semantic proximity Read ↗

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read ↗

Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.Semantic proximity Read ↗

Deep-sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.